TOKYO -- Japan's Eisai and American partner Biogen will transfer some production of active ingredients for their Alzheimer's disease treatment lecanemab to the U.S. amid concerns that President Donald Trump will slap tariffs on pharmaceuticals.
Pharmaceuticals
Biogen, Eisai to shift some Alzheimer's drug production to US
Eli Lilly, other drugmakers eye similar plans as Trump tariff countermeasure
Eisai and Biogen will start making some lecanemab active ingredients at a plant in North Carolina. (Eisai)
Read Next
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Pharmaceuticals
